Globally, synovial sarcoma remains a rare but aggressive malignancy with a 5-year survival rate of 70% to 80% and a 10-year ...
Speaker panel will include collaborative case study presentations from strategic partners: Memorial Sloan Kettering Cancer Center, Bio-Rad Laboratories, and Thermo Fisher Scientific ...
Iopofosine I 131 is a potential first-in-class, novel cancer targeting agent utilizing a phospholipid ether as a radioconjugate monotherapy. The FDA previously granted Orphan Drug Designation for ...
This quick mental health method can improve your outlook without a therapist, medicine, or months of commitment.
Visual content depicting climate activists emphasizes emotion and disruption, contrasting with the rational, data-driven ...
Contrary to fears of AI replacing jobs, a Harvard study reveals ChatGPT acts as a practical assistant for students and ...
The U.S. Food and Drug Administration (FDA) has granted rare pediatric drug designation for iopofosine-131 in inoperable relapsed or refractory pediatric high-grade glioma (pHGG), according to a news ...
The 2025 Annual Meeting of The Menopause Society, which took place October 21-25 in Orlando, included education sessions and ...
Evolve Therapy announced today that practice owner Renee Segal, MA, LMFT, will present at the Minnesota Association of ...
Alnylam Pharmaceuticals, Inc. is rated Hold due to high expectations, competitive threats, and revenue expansion. Learn more ...
Inflammatory cardiomyopathy remains a challenging condition characterized by inflammation of the heart muscle, which often results from a diverse range of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback